Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug

This article was originally published in PharmAsia News

Executive Summary

Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment

You may also be interested in...

Otsuka Plans ¥1 Trillion IPO To Expand Beyond Abilify And Soyjoy

Aiming at expanding beyond its blockbuster schizophrenia drug and widely popular personal care products, Japan's fifth-largest drug maker Otsuka Pharmaceutical is reportedly preparing an initial public offering in Tokyo estimated to be valued at over ¥1 trillion ($12 billion) based on calculations of the stock option exercise price, making Otsuka one of the largest Japanese drug makers to go public in a decade

Glaucoma's Changing Of The Guard

Despite a crowded marketplace - with at least seven marketed drugs in at least three different classes -glaucoma remains a disease with a huge unmet need

Otsuka Looks To IPO To Fund Overseas Expansion

Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts